Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in non-small cell lung cancer: A real-world study

被引：0
|
作者：
Wu, F. [1 ]
Wu, S. X. [1 ]
Hu, H. C. [1 ]
机构：
[1] Cent S Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Hunan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
475P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in non-small cell lung cancer: A real-world study.
    Wu, Fang
    Wu, Sixuan
    Hu, Chunhong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study
    Hu, Chunhong
    Wu, Sixuan
    Deng, Renfang
    Wu, Yuanqiang
    Pan, Yue
    Shu, Long
    Wu, Fang
    [J]. CANCER MEDICINE, 2023, 12 (01): : 266 - 273
  • [3] Real-World Study of EGFR-TKIs Combined With Radiotherapy in Patients With Brain Metastases From Non-small Cell Lung Cancer
    Liu, Yi
    Zhu, Yaning
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : S11 - S11
  • [4] The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study
    Yu, Xiaoqing
    Si, Jinfei
    Wei, Jingwen
    Wang, Yanling
    Sun, Yan
    Jin, Jianan
    Zhang, Xiaoyan
    Ma, Tonghui
    Song, Zhengbo
    [J]. CANCER MEDICINE, 2023, 12 (05): : 5630 - 5638
  • [5] Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer
    Yinan Yu
    Jianguo Zhao
    Jiaona Xu
    Rui Bai
    Zewei Gu
    Xialin Chen
    Jianfang Wang
    Xueying Jin
    Gaoyang Gu
    [J]. Current Treatment Options in Oncology, 2023, 24 : 1935 - 1947
  • [6] Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer
    Yu, Yinan
    Zhao, Jianguo
    Xu, Jiaona
    Bai, Rui
    Gu, Zewei
    Chen, Xialin
    Wang, Jianfang
    Jin, Xueying
    Gu, Gaoyang
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) : 1889 - 1916
  • [7] Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US
    Kong, Amanda M.
    Pavilack, Melissa
    Huo, Hairong
    Shenolikar, Rahul
    Moynihan, Meghan
    Marchlewicz, Elizabeth H.
    Chebili-Larson, Christina
    Min, Stella
    Subramaniam, Deepa S.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 328 - 338
  • [8] Clinical efficacy and safety of apatinib combined with EGFR-TKIs in advanced non-small cell lung cancer with EGFR-TKIs resistance
    Tian, Ruifen
    Guo, Yi
    Zhang, Xia
    Zhang, Xing
    Guo, Wei
    Zhu, Haibo
    Xu, Junjun
    Shen, Fangfang
    Song, Xia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
    Zhou, Jia-Ying
    Liu, Si-Yang
    Wu, Yi-Long
    [J]. EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) : 589 - 599
  • [10] A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs
    Cai, Ruoxue
    Liu, Ying
    Yu, Mingyan
    Sha, Huanhuan
    Guo, Mengya
    Chen, Yue
    Ye, Jinjun
    Zhou, Guoren
    Fang, Ying
    Shen, Bo
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (12) : 4355 - 4365
12345